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Abstract
Objective: To model the potential interaction between previously identified biomarkers in children sarcomas using artificial
neural network inference (ANNI).
Method: To concisely demonstrate the biological interactions between correlated genes in an interaction network map,
only 2 types of sarcomas in the children small round blue cell tumors (SRBCTs) dataset are discussed in this paper. A
backpropagation neural network was used to model the potential interaction between genes. The prediction weights and
signal directions were used to model the strengths of the interaction signals and the direction of the interaction link
between genes. The ANN model was validated using Monte Carlo cross-validation to minimize the risk of over-fitting and to
optimize generalization ability of the model.
Results: Strong connection links on certain genes (TNNT1 and FNDC5 in rhabdomyosarcoma (RMS); FCGRT and OLFM1 in
Ewing’s sarcoma (EWS)) suggested their potency as central hubs in the interconnection of genes with different
functionalities. The results showed that the RMS patients in this dataset are likely to be congenital and at low risk of
cardiomyopathy development. The EWS patients are likely to be complicated by EWS-FLI fusion and deficiency in various
signaling pathways, including Wnt, Fas/Rho and intracellular oxygen.
Conclusions: The ANN network inference approach and the examination of identified genes in the published literature
within the context of the disease highlights the substantial influence of certain genes in sarcomas.
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Introduction
Although computer technologies have evolved over the past
decades, debate regarding on the suitability of data mining
techniques to identify ‘‘true’’ biomarkers continues due to the fact
that these techniques are fundamentally based on mathematical
paradigms. Furthermore, the connection between the statistical
and the biological significance of the findings are not well
described and validated. Questions regarding the advantage of
these techniques and the relevance of the selected biomarkers to
biological processes might explain why very few biomarkers that
have been discovered using these approaches have seen clinical
applications.
Additionally, many of the published studies assumed that
biomarker discovery involves merely marker selection and
classification. Markers with high statistical power and able to
accurately predict the disease group are treated as ‘‘best’’ markers
for clinical use, even though their biological interactivities are not
tested in silico. This might explained why clinical trials on these
markers have failed. We believe that the identification and
validation of biomarkers in silico are equally important in
biomarker discovery and are vital for clinical trial development.
An in silico simulation of possible biological interaction between
the selected candidate markers provides information on the nature
of the markers (i.e. proactive or inactive), state of the markers (i.e.
on or off) and possible chemical changes on the markers. These
information can subsequently improve the success rate in clinical
trials and patient care. In short, the biology of phenotype is more
than just a list of markers; it is the complex interaction of biological
components that defines phenotype.
We previously identified a list of high potential marker
candidates that are able to differentiate small round blue cell
tumors (SRBCTs) in children [1]. This study builds on previous
work which has modeled the interaction between these markers to
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reveal their potential biological relevance in child sarcoma cancers
using a bespoke artificial neural network based interactive
algorithm.
The sarcoma groups in the SRBCTs dataset reported by Khan
et al. [2] were used in this study. The selection of biomarker panels
for the SRBCTs dataset was performed using a hybrid genetic
algorithm-neural network (GANN) model, as has been reported in
our previous work [1]. The aim of this GANN approach was to
identify sets of features that possess significant statistics information
and statistical comparison between classification methods based
upon gene sets reported by Khan et al. and the GANN model has
been elaborated. This study focused on modeling interactions
between these features in order to infer their potential biological
significance in sarcoma cancers.
It is difficult to objectively compare the biological relevance of
individual genes identified between studies, as complex biology
cannot be quantified using numerical analyses. Published literature
[3,4] has argued that the biological relevance between features can
be achieved using correlation analysis and a pre-defined baseline
value of the parameter which is known to be biologically
meaningful. However, this information alone is not sufficient for
comparing which feature has more biological meaning than
another, as the full biological function of the features and the
biochemical reaction mechanisms underlying regulatory interac-
tions between features cannot be fully known without conducting a
thorough assessment in clinical materials relevant to the disease
status in order to describe behaviors of these features in vivo. This
clinical assessment and validation is not within the remit of this
paper and instead of looking for more biological meaningful
features, this paper reports a complementary set of genes to those
reported by Khan et al [2].
For the sake of conciseness of the interpretation of the biological
relevance on the selected genes in the dataset, the biological
functionality of the genes associating with 2 types of sarcomas, and
interactions that are of potential relevance on the basis of plausible
biological explanations and the correlation analysis of the genes
were studied in this paper.
Materials and Methods
In this section, we describe the SRBCTs dataset and the selected
biomarkers by the GANN model. We then describe the framework
of the interactome network analysis constructed using ANNs.
Small round blue cell tumors (SRBCTs) dataset
The SRBCTs cDNA microarray dataset was originally studied
by Khan et al. [2], with the scope of identifying marker genes that
are able to distinguish 4 different types of blue cell tumors which
often masquerade as one another in childhood. This was
performed with ANN classification models in conjunction with
Principle Component Analysis (PCA). The original dataset
contained 88 samples with 2,308 genes, distributed into 4 different
tumor types, i.e. rhabdomyosarcoma (RMS), Ewing’s sarcoma
(EWS), Burkitt lymphoma (BL) and neuroblastoma (NB). Amongst
the 88 samples, 25 were in the RMS group, 29 in EWS, 11 in BL,
18 in NB and the remaining 5 samples were unknown.
Feature selection using genetic algorithm-neural
network (GANN)
The GANN is a hybrid model which we have previously applied
to the screening of datasets for genes of statistical relevance [1,5–
7]. In the GANN model, genetic algorithm (GA) and ANN co-
evolve in the learning process. In brief, a population of
chromosomes each representing a subset of microarray genes
was first generated and the fitness for each chromosome was
computed as a solution to the problem using multilayered ANNs.
These fitness values were then iteratively evaluated using GA’s
operators and ANNs, and a rank order of the genes based on their
fitness values was produced. The evaluation process was iterated
3,000 times and the whole process cycle was repeated 5,000 times.
The complete parameter settings on the GANN model can be
found in our work [1].
The previously reported panel of 96 genes [1] is summarized in
Table 1. Among these genes, 44 were complementary to the top
96 genes reported by Khan et al. [2].
Interactome Network Map
The concept of the interactome network map in which the
internal organization and functional regulation of cells can be
presented using network/graph theory was initially set out by
Baraba´si and Oltvai [8]. In the network map, a single gene is
symbolized by a node, and the link between genes is known as an
edge, which can be presented with an arrow to indicate the
direction of the link from a source node to a target node.
Interactome network maps have been used to demonstrate
interactions between biological components. These originally
utilized off-the-shelf or publicly available modeling tools to analyze
associations between biological molecules [9–13], but later used
customized data mining tools to comprehensively model the
interaction between biological molecules. These customized
regulatory networks were initially Boolean-based [14,15], then
evolved to Bayesian probability [16–18], dynamic ordinary
differential equations (ODEs) [19] and in recent years, ANNs
[20–25]. These and other approaches have been reviewed
elsewhere [26–30]. An ANN network inference approach was
chosen to model the interactions between sarcoma-related
microarray genes for the SRBCTs dataset in this study. For
reference, we refer to this approach as Artificial Neural Network
Inference (ANNI).
Artificial neural network inference (ANNI)
ANNs have been extensively used for biomarker identification
and classification [31–37] due to their ability to cope with
complexity and nonlinearity within the biology datasets. These
features enable ANNs to address a particular question by
identifying and modeling patterns in the data [38,39]. The
underlying structure of the multilayer perceptron (MLP) is a
weighted, directed graph [24], interconnecting artificial neurons
(i.e. nodes) organized in layers with artificial synapses (i.e. links)
which carry a value, (i.e. weight) transmitting data (i.e. signals)
from one node to the other nodes. All incoming signals from the
input layer will be processed based upon a set of defined
parameters (i.e. error computation function, acceleration measure,
input weights) by the nodes in the intermediate layer (i.e. hidden
layer) and an activation function is applied to the resulting sum.
This sum is then used to determine the output result (i.e. predicted
value) generated by the nodes in the output layer. Due to the
connectionist computation in ANNs, the architecture of the ANN
can be easily modified to address different questions and able to
compose complex hypotheses that can explain a high degree of
correlation between features without any prior information from
the datasets. Hence, a backpropagation MLP was chosen as ANN
to model the gene-gene interaction in this paper.
This study hypothesized that the expression (i.e. up- or down-
regulation) of a biomarker can be explained using the remaining
biomarkers in the gene pool, if these biomarkers are able to
explain one particular categorical outcome (i.e. a disease status).
Herein, we explored the influences of all biomarkers among
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Table 1. Summary of the previously selected 96 genes by GANN.
GANN rank Symbol Image Id. GeneID Truncated p-value for each cancer
EWS BL NB RMS
1 MLLT11 812105 10962 8.65610212 4.12610216 7.27610217 1.33610210
2 IGF2 207274 3481 1.03610207 5.65610211 7.74610206 4.78610209
3 FCGRT 770394 2217 1.03610213 6.87610213 5.69610210 2.27610207
4 CAV1 377461 857 5.21610211 1.00610210 1.02610208 8.49610208
5 FGFR4 784224 2264 5.20610208 5.44610208 2.90610208 8.32610211
6 CD99 1435862 4267 8.12610212 6.96610213 8.43610209 1.04610205
7 IGF2 296448 3481 1.33610207 9.71610210 5.37610205 7.89610209
8 MAP1B 629896 4131 1.30610205 4.24610211 1.90610207 1.41610204
9 KDSR 814260 2531 2.11610209 2.49610208 1.13610207 8.03610208
10 FNDC5 244618 252995 2.53610207 4.58610209 3.63610206 2.13610208
11 CDH2 325182 1000 9.87610207 4.86610207 2.95610208 1.41610204
12 OLFM1 52076 10439 3.29610208 2.29610210 1.26610203 1.77610208
13 RCVRN 383188 5957 1.00610207 4.69610214 8.68610208 4.22610203
14 PTPN13 866702 5783 2.74610208 9.53610209 1.26610206 2.33610207
15 HLA-DMA 183337 3108 3.76610204 1.90610207 1.15610206 2.84610204
16 MYL4 461425 4635 8.30610206 1.03610206 2.28610206 1.25610206
17 SGCA 796258 6442 1.83610207 1.02610206 5.97610207 2.05610208
18 GAP43 44563 2596 1.03610204 1.71610205 3.22610205 9.14610205
19 PSMB8* 624360 5696 2.76610203 1.72610206 2.00610205 1.16610206
20 PMS2L12* 878652 392713 2.25610203 4.03610211 3.34610207 9.49610204
21 EHD1* 745019 10938 1.13610205 1.38610209 2.90610204 1.45610203
22 TNNT2 298062 7139 3.20610205 1.70610205 1.97610205 1.91610205
23 CBX1* 786084 10951 3.86610208 1.76610203 1.86610209 2.85610203
24 RBM38 814526 55544 2.84610205 2.50610207 1.06610209 2.41610203
25 TNNT1 1409509 7138 4.90610205 4.05610207 5.91610206 3.63610206
26 CRMP1 878280 1400 1.12610204 2.46610211 4.80610207 1.90610203
27 HLA-DQA1 80109 3117 1.46610203 1.80610205 2.67610205 2.64610204
28 DPYSL4 395708 10570 7.62610204 1.63610210 3.05610206 5.67610205
29 PIM2 1469292 11040 2.74610203 6.31610206 9.72610206 1.36610205
30 CTNNA1 21652 1495 1.09610205 5.03610211 1.13610206 8.77610204
31 SELENBP1 80338 8991 2.12610207 2.77610210 1.46610208 7.56610204
32 ELF1 241412 1997 7.03610204 4.75610205 5.19610206 9.91610204
33 KIF3C 784257 3797 4.80610203 8.36610211 1.90610205 3.69610205
34 GYG2 43733 8909 9.70610207 5.56610208 8.77610206 1.03610205
35 LSP1* 143306 4046 1.22610205 4.34610210 4.77610204 6.24610207
36 MT1L 297392 4500 2.20610203 2.50610206 1.84610204 7.29610204
37 CHD3* 379708 1107 1.99610207 4.37610209 1.09610206 4.37610204
38 EST (CDK6) 295985 1021 3.08610210 3.26610203 2.66610206 1.63610204
39 TNFAIP6 357031 7130 7.93610207 1.92610207 3.07610206 1.34610205
40 WAS* 236282 7454 7.36610204 7.88610208 3.27610207 1.10610203
41 GAS1 365826 2619 1.72610204 4.78610211 4.69610209 2.04610203
42 HCLS1 767183 3059 1.42610203 6.05610206 3.06610206 1.66610204
43 MYO1B 377048 4430 2.41610205 2.77610215 5.34610207 1.71610202
44 ARPC1B* 626502 10095 1.37610203 8.58610205 1.49610204 1.47610203
45 HOXB7* 1434905 3217 4.75610207 4.65610206 1.80610211 1.89610202
46 PRKAR2B 609663 5577 3.77610204 2.19610205 4.23610203 1.16610207
47 G6PD* 768246 2539 1.67610205 2.72610203 7.13610206 5.18610204
48 GATA2 135688 2624 3.42610203 5.37610208 1.67610205 1.01610205
49 CSDA* 810057 8531 3.77610204 2.10610202 4.99610210 7.21610204
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Table 1. Cont.
GANN rank Symbol Image Id. GeneID Truncated p-value for each cancer
EWS BL NB RMS
43 MYO1B 308231 4430 3.59610205 2.84610211 5.94610206 1.31610202
51 EID1* 244637 23741 2.25610203 4.54610205 5.89610207 7.23610204
52 PSMB10* 68977 5699 1.24610203 2.80610205 3.74610204 1.76610203
53 FHL3* 796475 2275 2.56610205 3.26610211 4.42610207 5.07610203
54 ITPR3* 435953 3710 1.31610203 8.08610205 1.15610207 1.22610206
55 DPYSL2 841620 1808 2.99610205 4.26610215 2.83610204 5.63610207
56 BIN1 788107 274 2.93610205 2.53610207 3.05610203 1.97610205
57 PFN2 486110 5217 5.41610203 1.02610215 9.16610206 2.33610202
58 TLE2 1473131 7089 2.88610207 5.70610209 2.24610208 1.06610203
59 PGAM2* 283315 5224 3.25610203 1.21610205 2.51610202 5.78610208
60 ISG20* 740604 3669 9.18610204 1.04610204 1.26610204 7.18610204
61 RDX* 740554 5962 6.12610207 4.86610211 2.57610205 1.62610203
62 PPP1R18* 208699 170954 1.94610207 2.46610206 3.19610203 3.19610203
63 CCND1 841641 595 6.10610204 1.67610209 2.10610203 3.21610206
64 SMPD1* 729964 6609 3.03610205 2.00610208 1.07610204 2.74610203
65 MEIS3P1* 450152 4213 3.42610204 2.82610210 7.84610206 3.17610203
66 MYH10* 823886 4628 2.77610203 7.30610213 4.38610206 1.72610202
67 IFITM3 809910 10410 1.45610203 2.50610211 6.00610209 5.59610204
68 ARSB* 502055 411 2.91610204 9.78610210 2.01610202 4.32610203
69 BCKDHA* 740801 593 1.62610205 4.15610211 9.91610206 1.08610202
70 NF2* 769716 4771 3.40610204 3.62610207 6.50610209 9.26610208
71 CLEC3B* 345553 7123 1.24610203 2.45610204 1.07610203 2.73610203
72 HSPB2 324494 3316 1.77610202 1.37610209 2.10610209 1.74610206
73 NFKB1* 789357 4790 2.05610205 4.94610205 1.92610205 1.31610202
74 GNA11* 221826 2767 4.08610207 1.12610214 8.04610204 8.58610203
75 IGF2 245330 3481 7.93610204 4.43610204 8.16610204 7.51610204
76 APLP1 289645 333 1.39610203 1.10610211 1.18610205 8.82610208
77 NFIC* 265874 4782 1.18610204 3.84610209 2.50610205 1.90610202
78 TEAD4* 346696 7004 1.61610202 1.37610209 1.92610205 9.80610206
79 HLA-DPB1 840942 3115 3.38610202 7.46610206 4.75610205 8.64610204
80 HMGA1* 782811 3159 3.37610204 7.05610205 5.88610204 8.40610207
81 MEST* 898219 4232 1.06610205 2.25610206 5.69610205 1.20610206
82 PTPN12* 774502 5782 1.32610207 4.28610207 2.82610205 9.16610205
83 IGLL1* 344134 3543 2.55610203 7.44610205 7.19610206 3.55610202
84 PTTG1IP* 505491 754 5.37610206 1.63610212 4.99610203 1.83610203
85 AKAP7* 195751 9465 9.97610204 1.06610202 9.20610204 1.05610203
86 SERPINH1* 142788 871 1.73610202 3.87610211 3.42610204 1.14610204
87 SEPT4* 66714 5414 8.07610204 3.62610207 2.87610204 5.90610205
88 CITED2* 491565 10370 5.18610209 9.60610210 8.45610204 1.00610205
89 TXNRD1* 789376 7296 3.23610203 3.25610202 2.39610206 6.32610207
90 EST (RND3) 784593 390 1.92610206 1.30610213 1.51610204 7.13610204
91 TRIP6* 811108 7205 3.74610207 4.99610210 3.88610208 3.27610202
92 EST (YAP1) 308163 10413 3.09610205 7.70610216 4.73610209 8.68610204
93 TAF15* 1474955 8148 6.55610203 1.38610205 2.34610203 3.45610202
94 RXRG* 358433 6258 2.31610202 1.70610208 5.13610207 2.87610204
95 SERPING1 756556 710 2.82610203 2.01610209 2.45610205 7.04610203
96 MYL1* 628336 4632 1.74610203 1.72610203 2.51610202 1.51610203
*indicates complement genes. Truncated p-value is the product of p-value of the gene expression value by its rank order in the GANN model and subsequently adjusted
using Benjamini and Hochberg false discovery rate.
doi:10.1371/journal.pone.0102483.t001
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themselves and provide a complete view of all of the possibilities of
network interactions for all biomarkers. Therefore, the principle of
the algorithm is to show the relationship between genes from the
same pool, to shed light on how these molecules interact with each
other and to identify new relationships between these molecules by
iteratively calculating the influence that multiple variables may
have upon a single one. The main advantage of this algorithm lays
in its multi-factorial consideration of each input which allows the
magnitude of interaction (i.e. inhibitory, stimulatory, bi- or
unidirectional) of a given pair of parameters to be determined
on the basis of a matrix of full interaction, and by iteratively
examining the weights and prediction performance of each single
input expression from all the others within the set.
Figures 1 and 2 present a schematic and a diagrammatic
representation of the interaction algorithm, respectively. A
summary of the parameter settings for the algorithm is depicted
in Table 2.
Multilayer perceptron (MLP). A 3-layered MLP with
backpropagation learning and sigmoid activation function was
applied to model gene-gene interactions for sarcoma cancers in
SRBCTs data. To prevent any relationships being omitted in the
interaction analysis, iterative calculation of the influence that
multiple genes may have on a single gene was performed in the
following way: The process begins with the first input gene in the
gene pool, which was defined as an output node in the ANN and
omitted from the pool. The remaining genes were then used to
predict the omitted gene, and the weights of the trained ANN
model were stored. This process was repeated by omitting the
second input gene as an output node in ANN and the remaining
genes as the input nodes in ANN and so on. The process was
iterated until all the genes in the dataset were used as an output.
The average values of these iterations were then computed as the
interaction score values.
Figure 1. Overview of the interaction algorithm.
doi:10.1371/journal.pone.0102483.g001
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The learning process. Given the initial connection weight v
is randomized in-between range 21 to 1, uk is the sum linear
output value from the input signal x of node k and b is the bias
value, the input signal x and the output signal y of node k can be
expressed as follows:
xk~
Xn
i~1
vkixi ð1Þ
and
yk~f (ukzbk), ð2Þ
where v[ 1,2,3,:::,nf g is the connection weights of the input
signals x[ 1,2,3,:::,nf g and f(?) is the sigmoid activation function
which can be defined as:
f (v)~
1
1zexp({av)
, ð3Þ
where v is the local signal in the node and a is the slope parameter
of the sigmoid function.
In the iterative learning cycle, the weights are adjusted based on
the output error d (see Eq. 4), the total sum-of-squares error based
on the difference between the network output y and the target
output d of the sample case. In Eq. 4, N is the total number of
sample patterns and s is the sample pattern.
d~
1
2
XN
s~1
(ds{ys)
2 ð4Þ
If both the network output and the target output are identical,
no adjustment on the weight in the current learning cycle T is
required for this sample pattern and a new sample pattern is fed
into the network and the learning cycle continues. If the match is
not perfect, the adjustment of the weight Dv is the proportion of
the input signal xi of node k, the learning rate g and the size of the
error d:
Dv(T)~gdkxi ð5Þ
The new weight for the next learning cycle T+1 can then be
written as:
vki(Tz1)~vki(T)zDv(T) ð6Þ
To reduce the chance of trapping in endless learning cycle, a
momentum a is applied in the learning process and thus, the Eq. 6
can be rewritten as:
vki(Tz1)~vki(T)zgdk(T)xizavkj(T{1) ð7Þ
Interaction. To define an interaction map for the genes, the
weights of the trained ANN models were used to illustrate and
score the interaction between genes, such as the intensity of the
relationship between a source gene and a target gene, and the
nature of the relationship either stimulatory or inhibitory (i.e.
positive or negative sign in correlation result, respectively). The
Pearson correlation coefficient r with a cutoff value of 0.7 was
implemented in the algorithm to remove the least significant
interaction scores.
Monte-Carlo cross-validation (MCCV). To prevent the
ANN model from being over-trained, the MCCV strategy was
applied as follows. The sample set was randomly partitioned
(without replacement in the sample set) into 3 smaller groups:
training, test and validation, with the ratio of 0.6:0.2:0.2,
respectively. The training and test sets were used to train the
ANN model and the validation set was used to examine the
trained model. After the model was trained, all samples were re-
shuffled and re-partitioned into training, test, and validation sets.
This re-shuffle and re-partition process was repeated 50 times, and
each time, new different sets of training, test and validation
samples were randomly generated.
The entire process cycle was repeated 10 times for single gene.
The algorithm was coded in C and empirical work on simulated
dataset was presented in the subsequent section.
Visualization of interactome network maps
The Cytoscape software platform (version 2.8) for molecular
interaction display was used in this study. Cytoscape [40,41] is an
open-source software for analyzing complex biological networks
by visually interrogating the relationship of their components using
a variety of plug-ins.
Assessment of ANNI using a simulated dataset
A simulated dataset has been generated to assess the prediction
ability and the robustness of the optimum ANN parameters (see
Table 2) for correctly identify correlated features and to compute
their correlation values. This dataset was created using R and
contains 100 samples with 25,000 features in which 32 were highly
correlated, distributed into 2 major classes. Amongst these 25,000
features, 100 best predictive including 29 pre-defined correlating
features were pre-selected using a data mining algorithm.
Despite the obvious advantages of using well-characterised
simulated datasets for the testing of new analysis tools, it is
important to note that human biological data are complex and the
lack in the knowledge of actual biological correlation between
sample replicates, molecular relationship between a biological state
of a cell and transcript expression, biochemical reaction mecha-
nisms underlying regulatory interactions between features and
activity changes from one state to another. This makes artificial
data valuable for algorithm development, but is not of value for
comparing different methods.
To assess the predictive ability of the algorithm, criteria such as
number of hidden nodes used in the network, correlation analysis
comparing the predicted correlation scores for each pair of the
features with their actual correlation values, interaction signs
analysis comparing between the sign of the actual correlation value
and the sign of the predicted interaction score and true positive
rate (TPR) have been considered. Table 3 shows a summary of the
results.
High accuracy on the TPR, correlation result and predicted
interaction sign confirm the feasibility of this approach to
accurately identify the simulated features having strong correla-
tions. In terms of network architecture, there is no significant
improvement on TPR when the number of hidden nodes
increases, thereby suggesting that the number of hidden nodes
does not affect the predictive ability of the algorithm. A model with
2 hidden nodes performs equally good, or better than those
equipped with higher number of hidden nodes and lesser
Gene-Gene Interaction Modeling for Childhood Sarcomas
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computational time is needed to process the query. Thus, 2 hidden
nodes were implemented in the algorithm.
A full, comprehensive empirical validation on the algorithm can
be found in Lemetre’s PhD Thesis [42].
Results and Discussion
Analysis of all 96 genes from the interaction analysis produced a
matrix of (966(96–1)) 9,120 potential interactions (Figure 3). Due
to the high dimensionality and complexity of the interactions
between all genes, it clearly appeared that no relevant information
could be elucidated in the map. Thus, only the 96 strongest
associations (based upon the averaged values of the scores leading
from a given input to the output), each associated to one of the 96
genes, were imported in Cytoscape and are presented in Figure 4.
The consequence of this is that for each of these 96 genes, only the
strongest interaction among all interactions with the other 95
genes was modeled. This greatly simplified the map, and facilitated
the interpretation and understanding of the key features within the
map. Table 1 presents the list of 96 genes with its truncated p-
values based upon the product of the p-values and its rank order in
Figure 2. Diagrammatic representation of the interaction algorithm.
doi:10.1371/journal.pone.0102483.g002
Table 2. Summary of the interaction algorithm parameters.
Parameter Setting
Architecture N-2-1, where N= total number of genes 21
Learning algorithm Backpropagation
Activation function Sigmoid
Epochs 300
Threshold of mean squared error (MSE) 0.01
Window of MSE 100
Momentum 0.5
Learning rate 0.1
Pearson r cutoff 0.7
Cross-validation Monte Carlo cross-validation
Random reshuffle 50 times
Ratio (%) for training: testing: validation 60:20:20
Number of time the whole process repeat
for single variable
10
doi:10.1371/journal.pone.0102483.t002
Gene-Gene Interaction Modeling for Childhood Sarcomas
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102483
the GANN model. These truncated p-values are adjusted using
Benjamini and Hochberg false discovery rate procedure [43].
Genes (i.e. target genes) with most associations include MT1L,
HLA-DPB1, GATA2, OLFM1, FCGRT, TNNT1, and FNDC5.
The repetitive genes in the map were IGF2 in ranks 2, 7, and 75;
and MYO1B in ranks 43 and 50. These repetitive genes show
consistent expression pattern in which all 3 selected IGF2 genes
show high expression values and strong negative interactions in
RMS, and the 2 selected MYO1B genes are in non-sarcoma
group. Low truncated p-value (stringent p-value,0.005) for RMS-
and EWS-regulated genes are observed in Table 1.
RMS and EWS are soft tissue sarcomas that can be found
virtually anywhere in the body and share common clinical
characteristics, more frequently occurring in males than females
and normally found in children. Early-stage RMS patients are
often confused with EWS, consequently inducing lymphatic-
related cancer when the RMS tumor migrates to lymph node.
Although these tumors have similar clinical conditions, EWS is
commonly developed in bones, whereas RMS is more frequently
found in skeletal muscle. In the map, genes which have exhibited
an up-regulation in both RMS and EWS groups include
CTNNA1, GAS1, IFITM3, YAP1, SERPING1, CSDA, FHL3,
NFIC, TRIP6, TAF15, and RXRG.
CSDA is a repressor gene involved in various biological
processes including skeletal muscle tissue development and organ
growth. FHL3 is only expressed in skeletal muscle and could be
involved in tumor suppression and repression of MyoD expression.
IFITM3 is IFN-induced antiviral protein that plays a role in innate
immune response to virus infections. NFIC is a cellular
transcription factor involved in DNA binding transcription factor
activity. Although the function of TRIP6 is not fully understood, it
has been associated with ligand binding of the thyroid receptor in
the presence of thyroid hormone. TAF15 plays specific roles
during transcription initiation in RNA binding and it may be
involved in protein-protein-interaction. RXRG is a retinoic acid
(RA) receptor that regulates gene expression in various biological
processes, including skeletal muscle tissue development, heart
development, and response to hormone stimulus.
Rhabdomyosarcoma (RMS)
RMS is a connective tissue related cancer. The cause of this
sarcoma is unknown, but its development has been associated with
desmin, MyoD1 and myogenin (MYOG) [44]. MyoD1 is a
regulator involved in muscle regeneration and muscle cell
differentiation and MYOG is the muscle-specific transcription
factor that plays a role in the development of functional skeletal
muscle.
TNNT1 (mainly expressed in heart muscle) and FNDC5
(normally induced by the expression of PGC-1 alpha in muscle)
are two highly associated genes in the RMS cancer, which act as
target genes (i.e. interaction hubs) that interconnect genes which
also show high expression values in the RMS cancer. These 2
genes are bridged by FGFR4, which plays a role in the regulation
of cell proliferation, differentiation and migration.
TNNT1 interaction cluster. TNNT1 protein is inhibited by
genes RXRG, MYL1, RND3, FHL3 and FGFR4. Amongst these
genes, RXRG, MYL1 and FHL3 were complementary genes to
the genes reported by Khan et al.
RXRG is a tumor suppressor gene that mediates the anti-
proliferative effect of retinoic acid (RA), an essential metabolite of
vitamin A for the growth, development and cell differentiation of
vertebrate species. This protein suppresses tumor growth by
increasing the anti-proliferative effects of RA in the tumor cells.
MYL1 is the motor protein known for the role in muscle cell
activities including vesicle transportation inside the muscle cell. A
negative interaction on this protein indicates that tumor cells are
constrained in a particular location rather than move randomly.
FHL3 expressed only in skeletal muscle has been known by its role
in skeletal myogenesis [45–47], although its actual function is
unknown. This gene has been related to cell spreading and actin
stress fiber disassembly [46] and is involved in tumor suppression/
repression of MyoD expression. RND3 is a member of the Rho
family GTPase protein superfamily that acts as a negative
regulator in cytoskeletal organization. It is known to have a role
in myoblast fusion [48] and to be responsible for down-regulation
in focal adhesions and stress fibers. FGFR4 is a tyrosine kinase
receptor responsible for signal transduction activities in the cell.
Although the activity of this protein is undetectable in normal
tissues, it becomes active when a tumor is formed. High expression
of FGFR4 has been associated with advanced-stage in RMS
cancer and a poor survival rate [49].
Although over-expression of FGFR4 in the map (see Figure 4),
is inhibited by other low/moderately expressed genes, it may
suggest the formation of tumor cell in skeletal muscle. Over-
expression of FGFR4 may stimulate the expression of TNNT1; the
regulator for striated muscle contraction, despite the fact that a
negative interaction between these 2 genes was detected. Low
expression of FHL3, RXRG, MYL1 and RND3 may also
promote the mutation of TNNT1 genes due to a suppression of
the anti-proliferative effects of RA in the RMS cells. The low
activity of these genes might influence normal cell spreading, actin
stress fiber disassembly and, consequently, tumor cells migration.
TNNT1 is the diagnostic marker for nemaline myopathy [50,51].
The high expression value in mutated TNNT1 genes suggests that
RMS tumors may be congenital.
FNDC5 interaction cluster. FNDC5 protein expressed in
muscle is inhibited by RMS-expressed genes including TNNT2,
BIN1, SEPT4, MYL4 and HSPB2. Up-regulation of this gene
suggests that the increased level of irisin hormone [52,53]
promotes the beneficial effects of exercise on metabolic pathways.
TNNT2 and BIN1 are proteins that play important roles in
cardiac muscle development. Over-expression of TNNT2 has
been correlated to myocardial stunning in hemodialysis patients
[54,55], and the disruption of this gene could lead to impaired
cardiac development in the embryo and infant [56–58]. Deficiency
of the BIN1 gene has been correlated with cardiomyopathy.
SEPT4 is the nucleotide binding proteins highly expressed in heart
and brain. It regulates cytoskeletal organization during embryonic
and adult life [59]. MYL4 is the hexameric ATPase cellular motor
proteins that commonly found in embryonic muscle and adult
atria. Over-expression of this gene was normally found in patients
with hypertrophic cardiomyopathy and congenital heart diseases
[60]. HSPB2 is another protein that expressed in the heart and
skeletal muscles. Over-expression of this gene indicates the
efficient recovery of motor neurons following nerve injury [61].
In the map (Figure 4), observation on the over-expression
pattern on TNNT2, BIN1 and MYL4, moderately expression on
HSPB2 and SEPT4 is lowly expressed. This suggests that RMS
patients have low chance to develop cardiomyopathy due to high
expressions of TNNT2, BIN1, SEPT4 and HSPB2 in RMS
pathway could potentially suppress expression level of FNDC5.
Ewing’s sarcoma (EWS)
EWS is a bone malignancy which commonly affects areas
including the pelvis, femur, humerus and the ribs [44]. The cell
origin of this tumor is uncertain. However, this cancer has a
shared cytogenetic abnormality with the primitive neuroectoder-
mal tumor (PNET) which arises from the soft tissue or bone. The
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shared cytogenetic abnormality involves the EWS/FLI fusion in
t(11;22)(q24;q12), a signature marker for EWS/PNET from other
small round tumors [62].
Two of the highest associated genes observed were FCGRT and
OLFM1 (Figure 4). FCGRT and OLFM1 acted as interaction
hubs, in which FCGRT plays a role in interconnecting genes
associated to the EWS/FLI fusion and OLFM1 integrates variety
biological process performed by other genes.
FCGRT interaction cluster. FCGRT protein is known as
the promoter marker to EWS-FLI fusion, one of the common
cytogenetic abnormalities on the t(11;22) translocation for Ewing
tumors. In the map, highly expressed FCGRT was suppressed by
TLE2, CITED2, CAV1, PTTG1IP and KDSR. Amongst these
associated genes, CITED2 and PTTG1IP were in addition to
those genes reported by Khan et al.
CITED2 is a cardiac transcription factor responsible for
inhibiting transactivation activity of hypoxia-induced genes.
Mutation of this gene decreases its ability to mediate the
expressions of VEGF and PITX2C genes, suggesting that it may
play a role in the development of congenital heart disease [63].
Table 3. Summary of the assessment results.
No. of hidden nodes No. of features Person’s coefficient % of correctly assigned signs Ave. true positive rate (%)
2 32 0.805 89.16 93.16
100 0.865 91.26 70.33
5 32 0.653 80.31 89.00
100 0.871 90.89 68.50
10 32 0.607 79.32 92.66
100 0.866 88.55 81.16
doi:10.1371/journal.pone.0102483.t003
Figure 3. A complete interactome network map.
doi:10.1371/journal.pone.0102483.g003
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Over-expressed CITED2 induces resistance to cisplatin [64], a
commonly used chemotherapeutic drug for sarcomas and other
solid malignancies. CAV1 is another promoter marker associates
to EWS-FLI fusion. Over-expression of this gene promotes
metastasis on Ewing tumor [65,66]. PTTG1IP is the promoter
gene that has been correlated with the Runx2 gene expression in
osteoblastic differentiation and skeletal morphogenesis [67].
Runx2 is the master regulator of osteoblast differentiation and
study reviewed that blockade of this gene by EWS-FLI induce
osteoblast specification of a mesenchymal progenitor cell and thus,
disrupting interactions between Runx2 and EWS-FLI may
promote differentiation of the tumor cell [68]. TLE2 proteinTLE2
is the member of TLE family and its actual function is not well
known. It is believed that the expression of TLE family members is
required for EWS oncogenic transformation [62] and acts as
repressor protein in histone modification when recruited by
NKX2–2 gene [62,69]. NKX2–2 is the known immunohisto-
chemical marker for Ewing sarcoma [70]. KDSR is the murine
gene and has been known by its role in the development of spinal
muscular atrophy (SMA) disease in cattle [71]. Although its actual
function in human SMA is unknown, a study has claimed that the
mutation of this gene does not contribute significantly to the cause
of human SMA [72], rather that it associated with chromosomal
rearrangement in chronic lymphatic leukemia [73,74].
In Figure 4, over-expression of CAV1, KDSR and CITED2
inhibited up-regulated FCGRT suggests these EWS patients are
EWS-FLI affected sarcoma and have deficiency of cisplatin
controlled repression of EWS-FLI fusion. Low expression values
of TLE2 and PTTC1IP further indicate the promotion of tumor
cell differentiation and histone modification due to inhibition on
Runx2 and NKX2–2 genes.
OLFM1 interaction cluster. OLFM1 protein which has
abundant expression in brain has been associated to the biological
process in nerve tissue, is inhibited by GYG2, APLP1, CHD3,
TNFAIP6, and ARSB genes. This cluster shows the interaction
between wide ranges of glycoproteins, histone deacetylase and
Wnt signaling pathway. GYG2 and APLP1 are glycoproteins
expressed in liver and membrane, respectively. GYG2 is a self-
glucosylating protein found in chromosome X and involved in the
initiation reactions of glycogen biosynthesis and blood glucose
homeostasis. Over-expression of this gene resulted in excess
glycogen storage levels in liver and may lead to glycogenosis due to
the deficiency of liver phosphorylase. APLP1 is a membrane-
associated glycoprotein that is cleaved by secretases and up-
regulation of this protein reduced endocytosis of amyloid precursor
protein (APP), and makes more APP available for alpha-secretase
cleavage [75].
ARSB is a sulfatase protein responsible for protein fragmenta-
tion and mediating intracellular oxygen signaling. Deficiency of
this gene due to hypoxia leads to an accumulation of GAGs
protein in lysosomes, resulting to mucopolysaccharidosis [76].
CHD3 is part of a histone deacetylase complex participating in
chromatin remodeling. Histone deacetylase removes acetyl group
on a histone so that the DNA can be tightly wrapped by histones.
TNFAIP6 is a multifunctional protein that exhibited in many
pathological and physiological contexts. It plays important roles in
inflammation and tissue/bone remodeling. It acts as a protector by
suppressing tumor necrosis factor (TNFSF11)-induced bone
erosion caused by inflammatory processes in arthritis diseases,
and exhibits a homeostatic function by interacting with bone
morphogenetic protein 2 (BMP2) and TNFSF11 to balance
mineralization by osteoblasts and bone resorption by osteoclasts
[77]. The binding of TNFSF11 with GAGs and other proteins
ligands enhances its activity in various biological processes,
including leucocyte adhesion and anti-plasmin activity [78].
Figure 4. A simplified interactome network map for the 96 selected genes by ANN network inference algorithm. The red node is the
genes with high expression values in either of the sarcoma cancers. The gray node is the gene with high expression values in more than one cancer
groups in which one of these groups is sarcoma cancer. Yellow node is the genes with low expression values in both sarcoma cancers.
doi:10.1371/journal.pone.0102483.g004
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OLFM1 protein has been associated with Wnt signaling
pathway in which the activation of Wnt signaling pathway in
receptive endometrium suppresses the OLFM1 gene and leads to
ectopic pregnancy in humans [79]. Wnt signaling pathway plays a
critical role in the normal development of multiple neuroectoder-
mal tissues, cell degradation and cell death. This pathway has been
associated with neuroectodermal Ewing sarcoma [80], osteosar-
coma [81] and possibly embryogenesis [82].
In the map (Figure 4), up-regulation of the OLFM1 gene
suppresses the activities of extracellular inhibitors in Wnt signaling
pathway. This may promote tumor cell proliferation, learning
impairment, suffocation of normal cells (i.e. hypoxia) in ARSB and
a deficiency of APP for alpha secretase cleavage in EWS patients.
Alpha secretases have been implicated in the regulation of learning
and memory formation. Furthermore, over-expression of CHD3
in tumor cells accelerates the interactions between DNA and
nuclear proteins, and contributes to tumor cell differentiation,
proliferation and migration. Although the moderately expressed
genes GYG2 and TNFAIP6 suppress the activity of tumor
proliferation, intervention from over-expressed CHD3 and
down-regulated APLP1 and ARSB promote diversification of
Ewing tumors.
A triangular affair between Wnt signaling pathways, Fas/Rho
signaling pathways and intracellular oxygen signaling is observed
in the map. Down-regulated ARSB (mediates oxygen in intracel-
lular process) due to intervention of moderately expressed Fas
receptor PTPN13 (a large intracellular protein mediates pro-
grammed cell death and regulates Rho signaling pathway) fails to
activate inhibitors in Wnt signaling pathways (over-expression of
OLFM1). Both the Fas receptor and Wnt signaling pathways
mediate programmed cell death and the Rho signaling pathway
responsible for cell proliferation, apoptosis and gene expression.
The over-expression of PTPN13 was suppressed by OLFM1.
Conclusions
We have previously shown that assessing the statistical
significance of genes, based on classification accuracy alone, may
not be useful for cancer diagnosis, as classification results are
subject to the proposed computational methods and a lack of
biological association to those genes to provide a global view on
the development of the tumor of interest. Thus, this paper
discussed the feasibility of using ANNI to model the potential
interactions between the correlated genes in childhood sarcoma
cancers. This interaction information could be useful for other
researchers who are assessing the practicality of using these genes
as new target markers for sarcoma cancers in the clinical setting.
Due to the high dimensional and complexity of the interactions
between genes, this paper showed only the strongest association for
each of the genes, rather than the complete potential 9,120
interactions existing among them. Even so, this approach
highlighted that certain genes were highly influential on sarcoma
cancers.
Based on the interaction map, several observations on sarcoma
cancers in SRBCTs dataset were noted. The RMS patients in this
dataset are likely to be congenital (due to up-regulation of mutated
TNNT1 stimulated by FGFR4 and suppression of anti-prolifer-
ative effects of RA in FHL3, RXRG, MYL1 and RND3) and these
patients have a lower risk of developing cardiomyopathy (due to
over-expression in TNNT2, BIN1, SEPT4 and HSPB2 potentially
suppress the expression level of FNDC5). The EWS patients are
likely to be affected by EWS-FLI fusion (due to deficiency of
cisplatin controlled repression, up-regulation of CAV1, KDSR
and CITED2, and suppression of TLE2 and PTTC1IP) and
involves various signaling pathway complications including Wnt,
Fas/Rho and intracellular oxygen pathways (due to over-
expression in OLFM1 and CHD3, and low expression in APLP1
and ARSB).
Additional information: The proposed algorithm will be
available by contacting the corresponding author. Individuals
from all disciplines are invited to access the software on a
collaborative basis. Information on the development and back-
ground to the algorithm are publicly available in Lemetre’s PhD
thesis, which is referenced in the manuscript.
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